Výsledky vyhledávání - "Houssein Safa"

Akademický článek

15 years of patient-reported outcomes in clinical trials leading to GU cancer drug approvals: a systematic review on the quality of data reporting and analysisResearch in context

Autor: Mahati Paravathaneni, Houssein Safa, Vidhu Joshi, Monica K. Tamil, Jacob J. Adashek, Filip Ionescu, Savan Shah, Juskaran S. Chadha, Scott Gilbert, Brandon Manley, Adele Semaan, Heather S.L. Jim, Denise Kalos, Youngchul Kim, Philippe E. Spiess, Jad Chahoud

Publikováno v: EClinicalMedicine, Vol 68, Iss , Pp 102413- (2024)

Summary: Background: Standardized, high-quality PRO data reporting is crucial for patient centered care in the field of oncology, especially in clinical trials that establish standard of care. This study evaluated PRO endpoint design, conduct and rep

Externí odkaz: https://doaj.org/article/f8367ce4344b45879a82f1322cc3d99e

Zobrazit plný text záznamu

Akademický článek

Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseases

Autor: Pankti Reid, Sabina Sandigursky, Juhee Song, Maria A. Lopez-Olivo, Houssein Safa, Samuel Cytryn, Elizaveta Efuni, Maryam Buni, Anna Pavlick, Michelle Krogsgaard, Osama Abu-Shawer, Mehmet Altan, Jeffrey S. Weber, Osama E. Rahma, Maria E. Suarez-Almazor, Adi Diab, Noha Abdel-Wahab

Publikováno v: OncoImmunology, Vol 12, Iss 1 (2023)

ABSTRACTPatients with preexisting autoimmune disease (pAID) are generally excluded from clinical trials for immune checkpoint inhibitors (ICIs) for cancer due to concern of flaring pAID. In this multi-center, retrospective observational study, we com

Externí odkaz: https://doaj.org/article/e9e4bf95dfc442469304d1d2730ac304

Zobrazit plný text záznamu

Akademický článek

Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature

Autor: Houssein Safa, Daniel H Johnson, Van Anh Trinh, Theresa E Rodgers, Heather Lin, Maria E Suarez-Almazor, Faisal Fa’ak, Chantal Saberian, Cassian Yee, Michael A Davies, Sudhakar Tummala, Karin Woodman, Noha Abdel-Wahab, Adi Diab

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-11 (2019)

Abstract Background Myasthenia gravis (MG) is a rare but life-threatening adverse event of immune checkpoint inhibitors (ICI). Given the limited evidence, data from a large cohort of patients is needed to aid in recognition and management of this fat

Externí odkaz: https://doaj.org/article/e15faeb18fd048fe83f36c7b0f6564db

Zobrazit plný text záznamu

Akademický článek

Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature

Autor: Noha Abdel-Wahab, Houssein Safa, Ala Abudayyeh, Daniel H. Johnson, Van Anh Trinh, Chrystia M. Zobniw, Heather Lin, Michael K. Wong, Maen Abdelrahim, A. Osama Gaber, Maria E. Suarez-Almazor, Adi Diab

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-10 (2019)

Abstract Background Checkpoint inhibitors (CPIs) have revolutionized the treatment of cancer, but their use remains limited by off-target inflammatory and immune-related adverse events. Solid organ transplantation (SOT) recipients have been excluded

Externí odkaz: https://doaj.org/article/1e5b8723c93a4ea8a65ace19e65e5634

Zobrazit plný text záznamu

Akademický článek

Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss 2 (2021)

Background Immune checkpoint inhibitors (ICIs) are being used after allogeneic hematopoietic stem cell transplantation (alloHCT) to reverse immune dysfunction. However, a major concern for the use of ICIs after alloHCT is the increased risk of graft-

Externí odkaz: https://doaj.org/article/10e93fbbcd6b4e969d6a3f82162fa2d6

Zobrazit plný text záznamu

Akademický článek

Corrections to: Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-1 (2019)

Following publication of the original article [1], the authors reported an error in the Acknowledgments section. It should be read: ‘We are grateful to Mohsin Shah from the Department of Emergency Medicine at The University of Texas MD Anderson Can

Externí odkaz: https://doaj.org/article/0baceb951406421d9e20711309a6c018

Zobrazit plný text záznamu

Emerging Biomarkers in Immune Oncology to Guide Lung Cancer Management

Autor: Houssein Safa, Fawzi Abu Rous, Neel Belani, Hossein Borghaei, Shirish Gadgeel, Balazs Halmos

Publikováno v: Targeted Oncology. 18:25-49

Over the last decade, the use of targeted therapies and immune therapies led to drastic changes in the management lung cancer and translated to improved survival outcomes. This growing arsenal of therapies available for the management of non-small ce

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0e83b28c8fff0a974182b0ea24025cc
https://doi.org/10.1007/s11523-022-00937-3

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání